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Abstract 
Recurrent airway obstruction (RAO) is a main characteristic of horses with 
severe equine asthma syndrome. The presence of bacterial 
lipopolysaccharide (LPS) in the airways of horses is thought to play a crucial 
role in the clinical expression of this disorder. This study pharmacologically 
characterized the effect of LPS on the responsiveness of equine bronchial 
tissue. Equine isolated bronchi were incubated overnight with LPS (0.1-100 
ng/ml) and then stimulated by electrical field stimulation (EFS). The role of 
capsaicin sensitive-sensory nerves (capsaicin desensitization treatment), 
neurokinin-2 (NK2) receptors (blocked by GR159897), transient receptor 
potential vanilloid type 1 receptors (TRPV1; blocked by SB366791), and 
neurokinin A (NKA) were investigated. Untreated bronchi were used as 
control tissues. LPS (1 ng/ml) significantly increased the EFS-evoked 
contractility of equine bronchi compared with control tissues (+742±123 mg; 
P<0.001). At higher concentrations LPS induced desensitization to airways 
hyperresponsiveness (AHR; EC50: 5.9±2.6 ng/ml). Capsaicin desensitization 
and GR159897 significantly prevented AHR induced by LPS at EFS1-50Hz (-
197±25%; P<0.01). SB366791 inhibited AHR at very low EFS frequency 
(EFS1Hz -193±29%; P<0.01 vs. LPS-treated bronchi). LPS (1 ng/ml) 
significantly (P<0.01) increased 3.7±0.7 fold the release of NKA compared 
with control bronchi. LPS induces biphasic dysfunctional bronchial contractility 
due to the stimulation of capsaicin sensitive-sensory nerves, increased 
release of NKA, and activation of NK2 receptors, whereas TRPV1 receptors 
appear to play a marginal role in this response. The overnight challenge with 
low concentrations of LPS represents a suitable model to investigate 
pharmacological options that may be of value in the treatment of equine RAO. 
 
Keywords 
Severe equine asthma syndrome, recurrent airway obstruction, airways 
hyperresponsiveness; airway smooth muscle; lipopolysaccharide; neurokinin 
A. 
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1. Introduction 
Recurrent airway obstruction (RAO) is one of the main characteristics of 
horses with severe equine asthma syndrome, which has formerly been known 
as heaves [1]. RAO is characterized by cough, poor performance, increased 
mucus production, airway neutrophilic inflammation and airways 
hyperresponsiveness (AHR) leading to bronchial narrowing and airflow 
limitation. Horses affected by severe equine asthma syndrome show laboured 
breathing at rest following exposure to specific airborne agents, and reversible 
and reproducible airway obstruction related with the level of environmental 
exposures [1, 2]. Although in RAO-affected horses clinical remission can 
generally be achieved by moving horses to pasture or into an indoor low-
airborne dust environment, prolonged and/or repeated exacerbations of 
severe equine asthma syndrome may lead to irreversible ultrastructural 
changes in the lung, and induce persistent abnormal contractility of airway 
smooth muscle (ASM), even when ill horses are maintained in a low dust 
environment [1, 3]. 
Although the specific antigens involved in triggering severe equine asthma 
syndrome have not yet been identified, exacerbation of clinical signs in RAO-
affected horses are shown in animals stabled with straw bedding and fed hay, 
or following aerosolization of hay dust suspensions [4].  
Indeed, it has been widely recognized that hay is the most common source of 
organic dust in stables containing both inhalable inorganic and organic 
particles such as moulds, mites, and bacterial lipopolysaccharide (LPS, also 
called bacterial endotoxin) [4], the latter playing a crucial role in the clinical 
expression of severe equine asthma syndrome [5-7]. Studies have 
demonstrated that the increase in the levels of matrix metalloproteinases 
(MMPs), proteolytic enzymes produced in the course of inflammation, found in 
bronchoalveolar lavage fluid (BALF) from severe asthmatic horses following 
inhalation challenge with LPS is dose-dependent [8], and  that the 
inflammatory response in peripheral blood mononuclear cells from RAO-
affected equines upon stimulation with hay dust extract might be a result of a 
synergistic interaction between LPS and certain allergens [4]. Intriguingly, 
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Pirie and colleagues reported that [9], while the acute administration of LPS 
increased the BALF neutrophil count in symptomatic horses in a dose 
dependent manner, only high doses of endotoxin induced a significant 
deterioration in lung mechanics. However, these authors correctly highlighted 
that the failure to detect airway bronchoconstriction could have been biased 
by the bronchodilatory effects of the α2-agonist drug used to sedate horses 
required in order to carry out the methacholine bronchoprovocation test [9]. 
Despite such a large body of evidence concerning the relevance of endotoxin 
in severe equine asthma syndrome, and the recent endorsement provided by 
the Consensus Statements of the American College of Veterinary Internal 
Medicine (ACVIM) [1], very little is currently understood about the effect of 
LPS on the responsiveness of bronchial tissue in horses and how this 
response can be pharmacologically manipulated. We have therefore 
hypothesized that LPS may induce neurogenic inflammation by stimulating 
capsaicin sensitive-sensory nerves in the lung [10] through the activation of 
the transient receptor potential vanilloid 1 (TRPV1) – neurokinin A (NKA) – 
neurokinin-2 (NK2) receptor axis as has been suggested to occur in human 
airways [11].  
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2. Material and methods 
2.1. Ethical approval 
This study has been carried out in accordance with the EU Directive 
2010/63/EU concerning the protection of animals used for scientific purposes.  
In order to not specifically sacrifice animals for our research aims, airway 
tissues have been obtained from horses  killed in a slaughterhouse for food, in 
agreement with the current EU regulations 853/2004, 854/20014, 1069/2009, 
142/2011, and 1069/2009. As such this study does not require to be 
consistent with the ARRIVE guidelines. However, this study has been 
approved by the local Ethics Committee (Institutional Animal Care and Use 
Committee [IACUC] of the University of Rome “Tor Vergata”, Rome, Italy). 
 
2.2. Preparation of tissues 
Equine airways were collected from 16 healthy horses (10 castrated male and 
6 mares in anoestrus; aged 3.4±0.3 years; weight 385.3±29.5 kg). Tissues 
were placed into refrigerated (4-6°C) Krebs-Henseleit (KH) buffer solution 
(NaCl, 119.0 mmol; KCl, 5.4 mmol; CaCl2, 2.5 mmol; KH2PO4 mmol, 1.2 
mmol; MgSO4, 1.2 mmol; NaHCO3, 25.0 mmol; glucose, 11.7 mmol; pH 7.4) 
containing indomethacin (5 µM) and transported to the Laboratory of 
Respiratory Clinical Pharmacology at the University of Rome “Tor Vergata” 
(Italy) from a nearby abattoir. None of the animals were under 
pharmacological treatment or showed clinical or gross pathological signs of 
respiratory infections. 
The experimental procedures began on the same day as the slaughter of the 
animals. In the laboratory, airways were cut into rings (sub-segmental bronchi; 
thickness 1-2 mm; internal diameter 4-6 mm) and transferred into a 10 ml 
High Tech 8 Channels Manual Compact Organ Bath system (Panlab Harvard 
Apparatus, Spain) containing KH buffer solution (37°C, pH 7.4) and aerated 
with O2/CO2 (95:5%) [12, 13]. Internal diameter and thickness of bronchial 
rings were measured via videomorphometry as previously described [14]. 
Tissues were allowed to equilibrate and the KH buffer solution was constantly 
changed.  
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2.3. Preparation of drugs 
The following drugs were used: capsaicin (Sigma-Aldrich, Milan, Italy), 
GR159897 (Santa Cruz Biotechnology, Dallas, Texas, US), indomethacin 
(Sigma-Aldrich, Milan, Italy), LPS from E. coli 0111:B4  (Sigma-Aldrich, Milan, 
Italy), SB366791 (Santa Cruz Biotechnology, Texas, US). Capsaicin was 
dissolved in ethanol and then diluted in distilled water, indomethacin was 
dissolved in ethanol and then diluted in KH buffer solution, LPS was dissolved 
in distilled water, GR159897 and SB366791 were dissolved in dimethyl 
sulfoxide (DMSO). The maximal final concentrations of DMSO (0.1%) and 
ethanol (0.02%) achieved in the organ bath did not influence the response of 
isolated tissues, as previously reported [11, 15]. Appropriate dilutions were 
obtained in freshly prepared medium and stock solutions stored in small 
aliquots at -80°C until use. 
 
2.4. Tension measurement 
Bronchial rings were connected to isometric force transducers (Fort25, WPI, 
UK). The signal was amplified by a Powerlab 8/36 and Octal Bridge Amp 
system (AD instruments, UK), recorded and analyzed by using LabChart 7 
interface software (AD instruments, UK). Tissues were mounted on hooks, 
and attached with thread to a stationary rod and the other end tied with thread 
to an isometric force displacement transducer. Airways were allowed to 
equilibrate for 90 min whilst flushing with fresh KH buffer solution every 10 
min. Optimal passive tension was determined by gentle stretching of the 
tissues (resting tone: 2.0–2.5 g) during equilibration, as previously reported 
[15-18]. The isometric change in tension was measured by the transducer and 
the tissue responsiveness assessed by EFS delivered at 25 Hz. The rings 
were then washed three times and allowed to stabilize. 
 
2.5. Transmural stimulation  
EFS, also called transmural stimulation, was performed by placing tissues 
between two wire platinum electrodes (20 mm apart, Panlab Harvard 
Apparatus, Spain), connected to a 3165 multiplexing pulse booster stimulator 
(Ugo Basile, VA - Italy). In order to simulate ex vivo the vagal firing normally 
observed at the physiological frequency in vivo, bronchial rings were 
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contracted by EFS delivered at increasing frequencies (from 1 Hz to 50 Hz; 
5V, 10s, 0.5ms, biphasic pulse), as described elsewhere [18-22]. The 
contractile responses of equine bronchi evoked by EFS are mediated through 
vagal nerve stimulation [23], as it is tetrodotoxin sensitive [24, 25]. 
 
2.6. Study design 
Equine bronchial tissues were incubated overnight with KH buffer solution 
(control) or LPS administered at different concentrations (from 0.1 ng/ml to 
100 ng/ml). Some LPS-incubated tissues were pre-treated with the potent and 
selective NK2 receptor antagonist GR159897 administered at 0.3 µM (pKb: 
8.57), or with the potent and selective transient receptor potential vanilloid 
type 1 (TRPV1) antagonist SB366791 administered at 2 µM (pKb: 7.74) [26, 
27]. The final concentrations in the baths of antagonists used in this study 
were two logarithms greater than their pKb and IC50 values in order to 
selectively antagonize the targeted receptors [11].  
In some experiments, the influence of capsaicin sensitive-sensory nerves was 
assessed with regard to the EFS-evoked bronchial contractility. Equine 
isolated airways were initially desensitized by five consecutive administrations 
of capsaicin (10 µM, one hour apart from each other) as described elsewhere 
[15, 28], and then treated with LPS.  
The day after these treatments, equine bronchial rings were mounted into the 
isolated organ bath system and connected to the isometric force transducers 
for recording the contractile response of airway smooth muscle (ASM) in 
response to EFS as previously described [20]. 
 
2.7. Neurokinin A quantification 
The supernatant was collected in order to quantify the levels of neurokinin A 
(NKA) in response to LPS incubation. The release of NKA was measured by 
using a specific horse ELISA assay kit (MyBioSource, San Diego, CA, US) at  
450 nm in 96-well plates, according to the manufacturers’ instructions in 
triplicate experiments [11]. 
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2.8. Data analysis 
The contractile response of equine isolated airways was expressed in mg and 
the percentage of the contractile tone induced in control bronchi by each EFS 
frequency.  
The frequency-response curves (FRCs) to EFS were analyzed by using 
appropriate sigmoid models to calculate the effect, the maximal effect (Emax), 
and the frequency inducing 50% Emax (EF50). The fitting equation model was: 
Y=Bottom + (Top-Bottom)/(1+10^((LogEF50-X)*HillSlope)); where HillSlope 
described the steepness of the family of curves [29]. 
The concentration-response curves (CRCs) to LPS were also analyzed by 
using appropriate bell-shaped models to calculate the effect, the Emax, and the 
concentration of LPS inducing 50% Emax (EC50). The fitting equation model 
was: Span1=Plateau1-Dip, Span2=Plateau2-Dip, 
Section1=Span1/(1+10^((LogEC50_1-X)*nH1)), Section2=Span2/(1+10^((X-
LogEC50_2)*nH2)), Y=Dip+Section1+Section2; where Plateau1 and Plateau2 
were the plateaus at the left and right ends of the curve, Dip was the plateau 
level in the middle of the curve, nH1 and nH2 were the HillSlopes [29].  
The logarithm of the ratio between the ASM contractility in LPS-treated 
bronchi and that detected in control airways was also calculated in order to 
adequately quantify the stimulatory/inhibitory impact of the different 
concentrations of LPS on the contractile response of the bronchi to EFS [30]. 
Experiments were performed on n=8 bronchi collected from different horses 
and values are presented as mean ± standard error of the mean (SEM). Each 
single treatment was carried out by using specimens collected from the same 
animal, and experiments were repeated 8 times in samples originating from 8 
different horses. The levels of NKA were normalized for the wet weight of 
bronchial tissue and expressed as the ratio relative to the control bronchi. 
Statistical significance was assessed by t-test and two-way analysis of 
variance (ANOVA) with Bonferroni post-tests carried out when necessary, and 
statistical significance defined as P<0.05. Data analyses were performed 
using Prism 5 software (GraphPad Software Inc, La Jolla, CA, USA). 
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3. Results 
3.1. Baseline characteristics 
The baseline characteristics of the equine isolated airways used in this study 
are reported in Table 1. No significant baseline differences (P>0.05) were 
detected among the bronchial rings used in this study. 
 
Table 1. Baseline characteristics of the bronchial rings used in the study and the contractile 
response induced by five consecutive capsaicin administrations (10 µM) at hourly intervals  
as the protocol to induce desensitization. 
Wet weight (mg) Internal diameter (mm) Thickness (mm) Resting tone (g) Tissue responsiveness at EFS25Hz (mg) 
95.6±3.4 4.45±0.04 1.28±0.02 2.24±0.03 302.2±25.4 
Capsaicin sensitive-sensory nerves desensitization (contractile response expressed as mg)  
1st administration 2nd administration 3rd administration 4th administration 5th administration 
1,990.5±399.4a 1,120.7±228.8b 610.2±121.0c 360.5±82.0c 60.4±13.3c 
a. P<0.001 vs. resting tone 
b. P<0.05 vs. contractile response at 1st administration 
c. P<0.001 vs. contractile response at 1st administration 
 
Capsaicin (10 µM) induced a significant contractile response of equine 
isolated bronchi (P<0.001 vs. resting tone), and five consecutive capsaicin 
administrations resulted in a significant tachyphylaxis (P<0.05 vs. the first 
capsaicin administration) such that the last (5th) administration of capsaicin did 
not significantly modify the baseline bronchial tone (P>0.05 vs. resting tone) 
(Table 1). 
The desensitization procedure of capsaicin sensitive-sensory nerves, 
GR159897 administered at 0.3 µM and SB366791 administered at 2 µM did 
not significantly modify (P>0.05) either the baseline bronchial tone or the 
contractile response to transmural stimulation in control bronchi (data not 
shown). 
 
3.2. Impact of LPS on the FRC to transmural stimulation 
The overnight incubation with LPS administered at 1 ng/ml elicited a 
significant (P<0.001) increase in bronchial contractility (Emax: 1,056.00±123.80 
mg) induced by EFS1-50Hz compared with control tissues (Emax: 314.50±16.45 
mg). The overnight treatment of bronchial tissues with LPS administered at 
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0.1 ng/ml, 10 ng/ml and 100 ng/ml did not modify Emax elicited by transmural 
stimulation. Overall, no concentration of LPS altered the EF50 compared with 
control tissues, that ranged between 6.75 Hz to 9.47 Hz (Figure 1). 
 
Figure 1. Impact of overnight incubation of equine isolated bronchi with different 
concentrations of LPS on the FRC to EFS. Points represent the mean±SEM of experiments 
performed in n=8 different isolated bronchi from 8 different horses. ***P<0.001 vs. control 
(statistical significance assessed by two-way ANOVA). EFS: electrical field stimulation; FRC: 
frequency response curve; LPS: lipopolysaccharide. 
 
3.3. Impact of increasing concentrations LPS on the contractile response 
to transmural stimulation 
The challenge of equine isolated bronchi with increasing concentrations of 
LPS elicited a bell-shaped contractile response to EFS. LPS induced a potent 
AHR when administered at low concentrations (overall EC50_1: 0.46±0.06 
ng/ml; overall Emax at 1 ng/ml: +238.71±53.65% vs. control; P<0.05), whereas 
at higher concentrations LPS elicited a progressive desensitization to AHR 
(overall EC50_2: 5.85±2.62 ng/ml) (Figure 2). 
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Figure 2. Impact of overnight incubation of equine isolated bronchi with increasing 
concentrations LPS on the contractile response to transmural stimulation. Points represent 
the mean±SEM of experiments performed in n=8 different isolated bronchi from 8 different 
horses. EFS: electrical field stimulation; LPS: lipopolysaccharide. 
 
Specifically, the logarithmic analysis of the ratio between the ASM contractility 
in LPS-treated bronchi and that detected in control airways showed that 
significant (P<0.05) AHR was induced by LPS administered at 1 ng/ml and 10 
ng/ml when isolated bronchi were stimulated by low EFS frequencies (EFS1-
3Hz), and that significant (P<0.001) AHR to medium-high EFS frequencies 
(EFS10-50Hz) was elicited only when LPS was administered at 1 ng/ml. 
Conversely, the overnight incubation of equine isolated airways with higher 
concentrations of LPS (100 ng/ml) induced a significant (P<0.05) 
desensitization of the ASM contractility elicited by medium-high EFS 
frequencies (EFS10-50Hz) (Figure 3). 
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Figure 3. Fold changes expressed as logarithmic scale of the ratio between the ASM 
contractility induced by transmural stimulation in LPS-treated bronchi and that detected in 
control airways. *P<0.05, **P<0.01, and P<0.001 vs. unchanged ASM contractility (statistical 
significance assessed by two-way ANOVA with Bonferroni post-test). (Log10: 0). Values >0 
indicate AHR, whereas values <0 indicate desensitization to transmural stimulation. ASM: 
airway smooth muscle; AHR: airways hyperresponsiveness; LPS: lipopolysaccharide. 
 
3.4. Mechanisms leading to AHR in LPS-incubated equine airways 
The AHR induced in response to EFS1-50Hz induced by the overnight 
incubation of equine isolated airways with LPS administered at 1 ng/ml was 
significantly prevented by the desensitization of capsaicin sensitive-sensory 
nerves, as well as by specifically antagonising NK2 receptors with GR159897 
(-180.14±22.43% and -213.83±28.02, respectively; both P<0.01 vs. LPS-
treated bronchi). The selective antagonism of TRPV1 receptors with 
SB366791 significantly prevented the AHR induced in response to very low 
EFS
 
frequencies (EFS1Hz: -193.15±29.38%; P<0.01 vs. LPS-treated bronchi), 
but did not inhibit the AHR induced in response to higher EFS frequencies 
(EFS3-50Hz: +29.98±19.35%; P>0.05 vs. LPS-treated bronchi) (Figure 4). 
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Figure 4. Influence of capsaicin sensitive-sensory nerves (capsaicin desensitization 
treatment), NK2 receptor (blocked by GR159897), and TRPV1 (blocked by SB366791) on the 
AHR induced by LPS administered at 1 ng/ml on the transmural stimulation. The continuous 
line indicates the normalized contractility in control bronchi and SEM (dotted lines). **P<0.01 
vs. LPS-treated bronchi (statistical significance assessed by two-way ANOVA) and §§P<0.01 
vs. AHR induced by LPS on EFS1Hz (statistical significance assessed by t-test). AHR: airways 
hyperresponsiveness; EFS: electrical field stimulation; LPS: lipopolysaccharide; NK: 
neurokinin; TRPV1: transient receptor potential vanilloid type 1. 
 
The overnight incubation of equine bronchial rings with LPS administered at 1 
ng/ml LPS significantly (P<0.01) increased 3.72±0.73 fold the release of NKA 
compared with control bronchi. 
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4. Discussion 
The results of this study demonstrate for the first time that LPS may elicit both 
AHR and bronchial desensitization in equine airways, depending on the 
concentration. Specifically, overnight incubation with low concentrations (1 
ng/ml) of LPS induced strong AHR in response to transmural stimulation. 
Conversely, the overnight challenge with LPS at higher concentrations (100 
ng/ml) inhibited the bronchial contractility in response to medium-high EFS 
frequencies. The bronchial desensitization of equine airways induced by high 
concentrations of LPS confirms the results of our recent investigations carried 
out using human airways where we have demonstrated that the overnight 
treatment of human isolated bronchi with LPS administered at 100 ng/ml 
significantly inhibited the contractile tone in response to EFS25-50Hz [20].   
In the current study we found that the best fitting equation model to describe 
the impact of increasing concentrations of LPS on the EFS-evoked 
contractions was a bell-shaped CRC, in which the stimulatory response at 
low-medium concentrations was greater than that elicited at higher 
concentrations of endotoxin. Indeed, this pharmacological model is more 
complicated than the standard monotonic sigmoid CRCs, although in this 
study we have analyzed a sufficient number of data points to adequately 
define both phases of bronchial responsiveness.  
The classic mechanisms through which bell-shaped CRCs may be 
understood include the administration of drugs that both activate and inhibit 
transmembrane receptors, and the complicated stimulus-response 
relationships caused by the promiscuity of different receptors [31, 32]. Our 
findings suggest that the bell-shaped CRCs induced by LPS is related with 
initial AHR following exposure to low concentrations, followed by a second 
desensitization phase following exposure to higher concentrations. This bell-
shaped relationship seems to be due to the role of capsaicin sensitive-
sensory nerves in the bronchial responsiveness to LPS as the desensitization 
of capsaicin sensitive-sensory nerves induced by 5 consecutive 
administrations of capsaicin abolished the AHR induced by LPS. This 
evidence suggests that LPS acts on capsaicin sensitive-sensory nerves, and 
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that while low concentrations of endotoxin elicit sensitization of equine 
airways, higher concentrations of LPS induce tachyphylaxis and thus 
bronchial desensitization to transmural stimulation. This evidence further 
supports the pivotal role of capsaicin sensitive-sensory nerves in the 
modulation of bronchial contractility  as previously reported in both human and 
equine isolated airways in response to different stimuli [11, 15, 28, 33]. 
TRPV1 receptors have been suggested to play a crucial role in LPS-induced 
neurogenic inflammation, as LPS may directly and indirectly activate TRPV1 
receptors, at least in human, bovine and murine tissues [11, 34-38]. Our 
results clearly indicate that activation of TRPV1 receptors has only a partial 
role in the AHR induced by LPS in equine airways. Indeed, although the 
selective TRPV1 antagonist SB366791 prevented the LPS-induced AHR to a 
very low EFS
 
frequency (EFS1Hz), it was ineffective in preventing the AHR to 
higher EFS frequencies (EFS3-50Hz).  
Our evidence suggests that the impact of LPS on the bronchial 
responsiveness to transmural stimulation is mainly TRPV1-independent. To 
date, little is known concerning the mechanisms for the TRPV1-independent 
activation of capsaicin sensitive-sensory nerves that lead to neurogenic 
inflammation [39], although the activation of acid-sensitive ion channels 
(ASICs) or certain types of voltage-gated potassium channel, the increase in 
oxidative stress, the inhibition of NADH-oxido-reductase system and of other 
enzymes [40-43] have all been suggested as possible mechanisms.  
Certainly, the overnight challenge with LPS induces oxidative stress in human 
isolated airways by inhibiting the activity/levels of endogenous anti-oxidant 
agents, and by increasing the activity/levels of pro-oxidant factors [20]. 
Therefore, we cannot exclude that the same mechanisms may modulate the 
neurogenic inflammation observed in equine isolated bronchi. We have also 
demonstrated that the overnight challenge with LPS increases the release of 
NKA, and that blocking its specific receptor, NK2, by using the selective 
antagonist GR159897, prevents the AHR induced by endotoxin. Sensory 
neuropeptides, including NKA, are thought to be responsible for neurogenic 
inflammation in the respiratory tract [42, 44, 45], a condition that in equine 
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isolated airways facilitates the cholinergic pathways in the vagus nerve 
stimulated by a wide range of EFS frequencies. Therefore, we can conclude 
that the impact of LPS on the responsiveness of equine bronchi is mainly 
mediated by an increased activation of NK2 receptors due to enhanced 
release of NKA, whereas the role of TRPV1 receptors is mainly relegated to 
the activation of capsaicin sensitive-sensory nerves stimulated by very low 
EFS frequencies. 
This ex vivo study extends the study of Venugopal and colleagues concerning 
the modulation of neurokinin receptors in RAO-affected horses [46] who 
demonstrated that the expression of NK2 receptor was up-regulated in bronchi 
of RAO-affected horses, and that isolated airways of RAO-affected subjects 
were more responsive to NKA compared with those of normal horses. These 
findings, together with the evidence provided by our current research, indicate 
that the environmental exposure to bacterial LPS may represent a crucial 
factor in modulating the bronchial responsiveness of severe asthmatic 
equines.  
The biphasic effect of LPS on bronchial responsiveness of equine airways 
suggests that a sporadic and acute exposure to low concentrations of  
endotoxin in the lung may exert a protective bronchoconstriction at the level of 
sub-segmental bronchi that, in turn, prevents the delivery of LPS to small 
airways. Conversely, the chronic exposure to high concentrations of inhaled 
endotoxin may induce airway desensitization leading to dysfunctional 
response of ASM, a condition that allows LPS and further organic and 
inorganic particles to reach the distal airways and induce lung inflammation 
[1]. 
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5. Conclusions 
LPS has deleterious effects on equine airways by inducing dysfunctional ASM 
contractility due to the stimulation of capsaicin sensitive-sensory nerves, 
increased release of NKA, and activation of NK2 receptors. The findings of 
this study also suggest that the impact of LPS on equine airways is only 
minimally dependent on the activation of TRPV1 receptors. Therefore, 
antagonising NK2 receptors may have a beneficial impact at normalizing the 
ASM contractility and controlling clinical signs in severe asthmatic horses.  
Although targeting neurokinin receptors failed to show any clinical benefit in 
humans with asthma [47-50], this study suggests that well designed clinical 
trials are needed to assess whether selective NK2 receptor antagonists (i.e. 
SR48968) [51] and non-selective NK receptor antagonists (i.e. FK224, 
AVE5883, CS003, DNK333) [52-55] may have clinical effectiveness in 
equines with severe asthma. 
Finally, but no less important, our results suggest that the overnight challenge 
with low concentrations of LPS as described in this study represents a 
suitable ex vivo model to investigate the impact of drugs as possible treatment 
approaches for equine RAO. 
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